FDA releases draft guidance for clinical development of psychedelic drugs
The FDA has released draft guidance for researchers investigating psychedelic drugs as a potential treatment for medical conditions such as psychiatric or substance use disorders. “Psychedelic drugs show initial promise as potential treatments for mood, anxiety and substance use disorders. However, these are still investigational products,” Tiffany Farchione, MD, director of the